Can a cancer drug shrink birthmarks? bleomycin injections put to the test

NCT ID NCT07728825

Completed Disease control Sponsor: University Of Anbar Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial investigates whether injecting bleomycin directly into low-flow vascular malformations (abnormal clusters of blood or lymph vessels) in the head and neck can shrink them. Twenty participants will receive up to four sessions of the drug under local anesthesia. The main goal is to measure how much the lesion volume decreases after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bleomycin injected directly into the malformation
What this could lead to: If effective, this could offer a non-surgical option to shrink low-flow vascular malformations, potentially improving appearance and function.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply widely. Bleomycin can cause side effects like skin changes or, rarely, lung problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHATIC MALFORMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphatic Abnormalities lymphatic malformation vascular malformation venous hemangioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHATIC MALFORMATION VASCULAR MALFORMATIONS VENOUS MALFORMATION

Contacts and locations

Locations

Al-Fallujah Teaching Hospital

Fallujah, Al-Anbar Governorate, 54001, Iraq
Al-Najaf Al-Ashraf Teaching Hospital

Najaf, Najaf, 54001, Iraq
Al-Sadr Teaching Hospital

Najaf, Najaf, 54001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.